Resistance to nonnucleoside reverse-transcriptase inhibitors and prevalence of HIV type 1 non-B subtypes are increasing among persons with recent infection in Spain

Carmen de Mendoza; Carmen Rodriguez; Javier Colomina; Concepcion Tuset; Federico Garcia; Jose M Eiros; Angelica Corral; Pilar Leiva; Jesus Aguero; Julian Torre-Cisneros; Jose Pedreira; Isabel Viciana; Jorge del Romero; Ana Saez; Raul Ortiz de Lejarazu; Vincent Soriano; Spanish HIV Seroconverter Study Group

doi:10.1086/496982

Resistance to nonnucleoside reverse-transcriptase inhibitors and prevalence of HIV type 1 non-B subtypes are increasing among persons with recent infection in Spain

Clin Infect Dis. 2005 Nov 1;41(9):1350-4. doi: 10.1086/496982. Epub 2005 Sep 29.

Authors

Carmen de Mendoza¹, Carmen Rodriguez, Javier Colomina, Concepcion Tuset, Federico Garcia, Jose M Eiros, Angelica Corral, Pilar Leiva, Jesus Aguero, Julian Torre-Cisneros, Jose Pedreira, Isabel Viciana, Jorge del Romero, Ana Saez, Raul Ortiz de Lejarazu, Vincent Soriano; Spanish HIV Seroconverter Study Group

Affiliation

¹ Service of Infectious Diseases, Hospital Carlos III, Madrid, Spain.

PMID: 16206115
DOI: 10.1086/496982

Abstract

The prevalence of drug resistance mutations was 12.1% among 198 persons who experienced human immunodeficiency virus (HIV) seroconversion identified in Spain during 1997-2004. There was a significant increase of K103N and of non-B subtypes over time. Transmission of HIV infection around the time of seroconversion was shown in 8 couples and in 2 clusters of 3 individuals.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Adult
Drug Resistance, Viral*
Female
HIV Infections / drug therapy*
HIV Infections / epidemiology*
HIV-1 / drug effects*
Humans
Male
Prevalence
Reverse Transcriptase Inhibitors / pharmacology
Reverse Transcriptase Inhibitors / therapeutic use*
Spain / epidemiology
Time Factors

Substances

Reverse Transcriptase Inhibitors